10-Valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: study protocol for a randomised controlled trial

Victor Oguoma, Nicole Wilson, Kim Mulholland, Mathuram Santosham, Paul Torzillo, Peter McIntyre, Heidi C Smith-Vaughan, Anne Balloch, Mark Chatfield, Deborah Lehmann, Michael J Binks, Anne B Chang, Jonathan Carapetis, Vicki Krause, Ross Andrews, Tom Snelling, Paul Licciardi, Peter S. Morris, Amanda Jane Leach

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)
62 Downloads (Pure)

Fingerprint

Dive into the research topics of '10-Valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: study protocol for a randomised controlled trial'. Together they form a unique fingerprint.

Medicine & Life Sciences